Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

SIMPLE SUMMARY: The aim of this study was to evaluate the predictive and prognostic value of the systemic immune-inflammation index (SII), which is based on peripheral blood platelet, neutrophil, and lymphocyte counts, in patients with metastatic renal cell carcinoma (mRCC) treated with ipilimumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: Stühler, Viktoria, Herrmann, Lisa, Rausch, Steffen, Stenzl, Arnulf, Bedke, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221331/
https://www.ncbi.nlm.nih.gov/pubmed/35740636
http://dx.doi.org/10.3390/cancers14122972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221331/
https://www.ncbi.nlm.nih.gov/pubmed/35740636
http://dx.doi.org/10.3390/cancers14122972

Ejemplares similares